Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPALA Protocol
2024-514103-33-00Phase 2Authorised
- Sponsor
- CHU de Lille
- Start
- May 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and 5-aminolevulinic acid in pleural mesothelioma, sponsored by CHU de Lille. Primary endpoint: Feasibility of full multimodal treatment without unacceptable toxicity. Planned start May 2022; status: authorised.
02
Drugs
nivolumab5-aminolevulinic acid
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on 2024-514103-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514103-33-00.